Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify the appropriate dose of irinotecan by dose
escalation(dose climbing) test. The study would provide rationale for regimen decision in a
future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be
selected as therapeutic drugs.